Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
Genelux(GNLX.US) 10% Shareholder Sells US$155.65K in Common Stock
$Genelux(GNLX.US)$ 10% Shareholder Szalay Aladar sold 44,395 shares of common stock on Apr 22, 23, 24, 2024 at an average price of $3.506 for a total value of $155.65K.Source: Announcement What is sta
Have Genelux Insiders Been Selling Stock?
We'd be surprised if Genelux Corporation (NASDAQ:GNLX) shareholders haven't noticed that an insider, Aladar Szalay, recently sold US$256k worth of stock at US$3.59 per share. On the bright side, th
Genelux(GNLX.US) 10% Shareholder Sells US$256.23K in Common Stock
$Genelux(GNLX.US)$ 10% Shareholder Szalay Aladar sold 71,420 shares of common stock on Apr 16, 17, 2024 at an average price of $3.5876 for a total value of $256.23K.Source: Announcement What is statem
Genelux Insider Sold Shares Worth $256,227, According to a Recent SEC Filing
Aladar Szalay, 10% Owner, on April 16, 2024, sold 71,420 shares in Genelux (GNLX) for $256,227. Following the Form 4 filing with the SEC, Szalay has control over a total of 4,113,885 shares of the com
Form 144(Amend) | Genelux(GNLX.US) 10% Stockholder Proposes to Sell 2.1 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 15, $Genelux(GNLX.US)$ 10% Stockholder SZALAY 2010 RETAINED ANNUITY TRUST intends to sell 494.74K shares of its common stock on Apr 15, with a total market value of approxi
Form 144 | Genelux(GNLX.US) 10% Stockholder Proposes to Sell 2.1 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 11, $Genelux(GNLX.US)$ 10% Stockholder SZALAY 2010 RETAINED ANNUITY TRUST intends to sell 494.74K shares of its common stock on Apr 15, with a total market value of approxi
Genelux Corp Unveils Strategic Corporate Outlook Presentation
After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX)
Benchmark Reiterates Speculative Buy on Genelux, Maintains $30 Price Target
Benchmark analyst Bruce Jackson reiterates Genelux with a Speculative Buy and maintains $30 price target.
Genelux Is Maintained at Buy by HC Wainwright & Co.
Genelux Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Genelux, Lowers Price Target to $32
HC Wainwright & Co. analyst Emily Bodnar maintains Genelux (NASDAQ:GNLX) with a Buy and lowers the price target from $35 to $32.
Genelux Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 499.25% HC Wainwright & Co. $35 → $32 Maintains Buy 11/27/2023 555.43% HC Wainwright & Co. → $3
Analysts Offer Insights on Healthcare Companies: Genelux Corp. (GNLX), Adicet Bio (ACET) and Entera Bio (ENTX)
Genelux Corp. Unveils New Corporate Presentation for Future Strategy
Genelux 4Q Loss/Shr 25c >GNLX
Genelux 4Q Loss/Shr 25c >GNLX
Genelux Q4 EPS $(0.25) Misses $(0.19) Estimate, Cash Balance of $23.2M
Genelux (NASDAQ:GNLX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.19) by 31.58 percent.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersRegulus Therapeutics (NASDAQ:RGLS) stock moved upwards by 84.8% to $2.55 during Tuesday's pre-market session. The company's market cap stands at $51.5 million. Assure Hldgs (NASDAQ:IONM) stock
12 Health Care Stocks Moving In Friday's After-Market Session
GainersTalphera (NASDAQ:TLPH) shares moved upwards by 15.6% to $1.3 during Friday's after-market session. The company's market cap stands at $22.0 million. As per the news, the Q4 earnings report came
Genelux Corp. Unveils Future-Oriented Corporate Presentation
No Data